Your browser doesn't support javascript.
loading
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial.
Sudhan, Dhivya R; Schwarz, Luis J; Guerrero-Zotano, Angel; Formisano, Luigi; Nixon, Mellissa J; Croessmann, Sarah; González Ericsson, Paula I; Sanders, Melinda; Balko, Justin M; Avogadri-Connors, Francesca; Cutler, Richard E; Lalani, Alshad S; Bryce, Richard; Auerbach, Alan; Arteaga, Carlos L.
Afiliación
  • Sudhan DR; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Schwarz LJ; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Guerrero-Zotano A; Oncosalud-AUNA, Lima, Peru.
  • Formisano L; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Nixon MJ; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Croessmann S; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • González Ericsson PI; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Sanders M; Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Balko JM; Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Avogadri-Connors F; Department of Pathology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Cutler RE; Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Lalani AS; Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Bryce R; Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
  • Auerbach A; Puma Biotechnology Inc., Los Angeles, California.
  • Arteaga CL; Puma Biotechnology Inc., Los Angeles, California.
Clin Cancer Res ; 25(2): 771-783, 2019 01 15.
Article en En | MEDLINE | ID: mdl-30274983
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Estrógenos / Receptor ErbB-2 Tipo de estudio: Clinical_trials Límite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptores de Estrógenos / Receptor ErbB-2 Tipo de estudio: Clinical_trials Límite: Animals / Female / Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article Pais de publicación: Estados Unidos